Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical care.

IF 2.8 Q1 Nursing

Technical Innovations and Patient Support in Radiation Oncology Pub Date : 2025-08-05 eCollection Date: 2025-09-01 DOI:10.1016/j.tipsro.2025.100326

Elena Moreno-Olmedo, Kasia Owczarczyk, Eliot Chadwick, Peter Dickinson, Aileen Duffton, Bleddyn Jones, James S Good, Fiona McDonald, Louise J Murray, Thomas Rackley, Maxwell Robinson, Judith Sinclair, Thomas Strawson-Smith, Alison Tree, Yat Man Tsang, Anjali Zarkar, Christopher Dean, Patricia Díez, Matt Williams, Nicholas Andratschke, Rebecca Muirhead

{"title":"Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical care.","authors":"Elena Moreno-Olmedo, Kasia Owczarczyk, Eliot Chadwick, Peter Dickinson, Aileen Duffton, Bleddyn Jones, James S Good, Fiona McDonald, Louise J Murray, Thomas Rackley, Maxwell Robinson, Judith Sinclair, Thomas Strawson-Smith, Alison Tree, Yat Man Tsang, Anjali Zarkar, Christopher Dean, Patricia Díez, Matt Williams, Nicholas Andratschke, Rebecca Muirhead","doi":"10.1016/j.tipsro.2025.100326","DOIUrl":null,"url":null,"abstract":"<p><p>Stereotactic ablative body radiotherapy (SABR) is routinely used for the management of oligometastatic disease. Increasingly, there is overlap of targets or organs at risk with previous radiotherapy fields. As substantial variation in delivery of clinical practice exists, the UK SABR Consortium worked with a collaborative national group to develop pelvic SABR re-irradiation consensus guidelines. The scope of the guidance includes patient selection criteria, pre-treatment considerations, delineation guidelines, dose prescription, calculations of cumulative dose constraints, and optimal planning technique. This guidance is part of an ongoing national prospective audit in collaboration with the Royal College of Radiologists and EORTC ReCare.</p>","PeriodicalId":36328,"journal":{"name":"Technical Innovations and Patient Support in Radiation Oncology","volume":"35 ","pages":"100326"},"PeriodicalIF":2.8000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12356378/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Technical Innovations and Patient Support in Radiation Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.tipsro.2025.100326","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Nursing","Score":null,"Total":0}

引用次数: 0

Abstract

Stereotactic ablative body radiotherapy (SABR) is routinely used for the management of oligometastatic disease. Increasingly, there is overlap of targets or organs at risk with previous radiotherapy fields. As substantial variation in delivery of clinical practice exists, the UK SABR Consortium worked with a collaborative national group to develop pelvic SABR re-irradiation consensus guidelines. The scope of the guidance includes patient selection criteria, pre-treatment considerations, delineation guidelines, dose prescription, calculations of cumulative dose constraints, and optimal planning technique. This guidance is part of an ongoing national prospective audit in collaboration with the Royal College of Radiologists and EORTC ReCare.

Abstract Image

查看原文本刊更多论文

盆腔立体定向消融体放疗（SABR）再照射：英国SABR联盟用于常规临床护理的指南。

立体定向消融体放射治疗（SABR）通常用于治疗少转移性疾病。越来越多的有危险的目标或器官与以前的放射治疗领域重叠。由于临床实践中存在实质性的差异，英国SABR联盟与一个合作的国家小组合作制定了骨盆SABR再照射共识指南。指南的范围包括患者选择标准、治疗前注意事项、划定指南、剂量处方、累积剂量限制的计算和最佳规划技术。该指南是与皇家放射科医师学院和EORTC ReCare合作进行的国家前瞻性审计的一部分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊